Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Abstract

Background: Previously, we showed that gene suppression commonly occurs across chromosome 2q14.2 in colorectal cancer, through a process of long-range epigenetic silencing (LRES), involving a combination of DNA methylation and repressive histone modifications. We now investigate whether LRES also occurs in prostate cancer across this 4-Mb region and whether differential DNA methylation of 2q14.2 genes could provide a regional panel of prostate cancer biomarkers.Methods: We used highly sensitive DNA methylation headloop PCR assays that can detect 10 to 25 pg of methylated DNA with a specificity of at least 1:1,000, and chromatin immunoprecipitation assays to investigate regional epigenetic remodeling across 2q14.2 in prostate cancer, in a cohort of 195 primary prostate tumors and 90 matched normal controls.Results: Prostate cancer cells exhibit concordant deacetylation and methylation of histone H3 Lysine 9 (H3K9Ac and H3K9me2, respectively), and localized DNA hypermethylation of EN1, SCTR, and INHBB and corresponding loss of H3K27me3. EN1 and SCTR were frequently methylated (65% and 53%, respectively), whereas INHBB was less frequently methylated.Conclusions: Consistent with LRES in colorectal cancer, we found regional epigenetic remodeling across 2q14.2 in prostate cancer. Concordant methylation of EN1 and SCTR was able to differentiate cancer from normal (P < 0.0001) and improved the diagnostic specificity of GSTP1 methylation for prostate cancer detection by 26%.Impact: For the first time we show that DNA methylation of EN1 and SCTR promoters provide potential novel biomarkers for prostate cancer detection and in combination with GSTP1 methylation can add increased specificity and sensitivity to improve diagnostic potential. Cancer Epidemiol Biomarkers Prev; 20(1); 148-59. Ó2011

BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

“…The detection of methylated DNA as a biomarker of disease has several advantages over protein-based assays as defined regions of cancer-specific hypermethylated-DNA can be readily amplified from samples collected noninvasively using PCR-based technology (38). In addition, panels of DNA methylation probes specific to multiple genes can be readily assembled to further inform diagnosis, as shown for lung cancer (39), ovarian cancer (40), and prostate cancer (41). Although the detection of methylated BCL-2 has not been assessed in breast cancer patient serum, recent publications describe the detection of BCL-2 methylation in blood samples derived from patients with pancreatic cancer (42), and in urinary samples used to detect and monitor bladder cancer (43).…”

Expression and significance of notch signaling pathway in salivary adenoid cystic carcinoma

“…where it activates transcription via CSL (also termed CBF-1 or RBP-Jx). CSL/Notch interactions induce target gene expression, including expression of members of the Hes and Hey families of transcription factors that ultimately prevent cell differentiation 8–10 .…”

Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells

“…These data suggest that improvement of epigenetic therapies may be achieved by designing strategies with long lasting effects. [3][4][5][6][7][8][9][10] Histone modifications can lead to either activation or repression depending upon which residues are modified and the type of modification. 11 For instance, in histone 3, dimethylaton and trimethylation of lysine 4 (H3K4me3) are associated with transcriptional activity, while trimethylation of lysine 27 (H3K27me3) is characteristic of silenced promoters.…”